Exhibit 99.2
FOR IMMEDIATE RELEASE | Contacts: | Ben Gong | 408-523-2175 | |||
Sarah Norton | 408-523-2161 |
INTUITIVE SURGICAL ANNOUNCES RECORD $27.6 MILLION FOURTH QUARTER REVENUE, UP 30%
SUNNYVALE, CALIF. February 12, 2004 – Intuitive Surgical, Inc. (NASDAQ: ISRG), the leader in operative surgical robotics, today reported fourth quarter 2003 sales of $27.6 million, increasing 30% from $21.1 million for the fourth quarter of 2002. Higher sales were driven by continued recurring revenue growth and shipments ofda Vinci® Surgical System fourth arm upgrades. Fourth quarter 2003 recurring revenue, consisting of instrument, accessory, service and training revenue, totaled $10.1 million, up 107% over the prior year and up $2.2 million, or 28%, sequentially from the third quarter of 2003. Recurring revenue increased to 37% of total sales from 23% during the fourth quarter of 2002.
Intuitive shipped 18da Vinci® Surgical Systems during the fourth quarter 2003, compared to 17 during the fourth quarter of 2002. Intuitive ended 2003 with 210 cumulativeda Vinci® Surgical Systems sold. Intuitive also shipped 11 additional fourth arms during the fourth quarter 2003. Overall fourth quarter 2003 system revenue increased to $17.5 million from $16.3 million during the fourth quarter 2002.
Sales for 2003 totaled $91.7 million for the year, up 27% from $72.0 million in 2002. Recurring revenue totaled $29.9 million in 2003, compared to $15.7 million in 2002. Intuitive sold 61 totalda Vinci® Surgical Systems and 37 fourth surgical arms in 2003 compared to 60 systems and no fourth arms in the previous year. The following table compares fourth quarter and fiscal year 2003 revenue to the prior year.
Page 1 of 7
3 Months Ended | Fiscal Year Ended | |||||||||||||||||
12/31/03 | 12/31/02 | Var. | 12/31/03 | 12/31/02 | Var. | |||||||||||||
Revenue ($ Millions) | ||||||||||||||||||
Systems | $ | 17.5 | $ | 16.3 | $ | 1.2 | $ | 61.8 | $ | 56.3 | $ | 5.5 | ||||||
Instruments/Accessories | $ | 6.1 | $ | 3.1 | $ | 3.0 | $ | 18.8 | $ | 10.1 | $ | 8.7 | ||||||
Service/Training | $ | 4.0 | $ | 1.7 | $ | 2.3 | $ | 11.1 | $ | 5.6 | $ | 5.5 | ||||||
$ | 27.6 | $ | 21.1 | $ | 6.5 | $ | 91.7 | $ | 72.0 | $ | 19.7 | |||||||
da Vinci®Surgical System Population | ||||||||||||||||||
Placements | 18 | 17 | 1 | 61 | 60 | 1 | ||||||||||||
Cumulative Placements | 210 | 149 | 61 | 210 | 149 | 61 |
During the fourth quarter of 2003, Intuitive recognized $5.5 million for charges to impair intangible assets and write-down excess inventory related to Computer Motion Aesop products, of which $5.3 million was charged to cost of sales. Also during the fourth quarter 2003, Intuitive recorded the settlement of its litigation with Brookhill Wilk for $2.6 million, of which $0.6 million was charged to fourth quarter cost of sales. The remaining $2.0 million will be amortized into cost of sales over approximately the next six years on a straight-line basis.
Intuitive reported fourth quarter 2003 gross profit of 34.6%, including the 21.3% impact of the Aesop and Wilk charges described above, compared to 50.7% reported for the fourth quarter 2002. The improvement in 2003 gross margin, excluding the Aesop and Wilk charges, was driven by lower product material costs, product reliability improvements, and productivity.
Fourth quarter 2003 operating expenses of $15.1 million increased $1.4 million from fourth quarter 2002 operating expenses of $13.7 million. Total fiscal year operating expenses increased 3% to $55.9 million in 2003 from $54.1 million in 2002.
Intuitive reported a fourth quarter 2003 net loss of $4.9 million, or $0.16 per share, including the $6.1 million of Aesop and Wilk charges. During the fourth quarter 2002, Intuitive reported a net loss of $2.6 million, or $0.14 per share. Intuitive reported a fiscal year 2003 net loss of $9.6 million, or $0.41 per share, compared to a net loss of $18.4 million, or $1.01 per share in fiscal 2002.
Page 2 of 7
During the fourth quarter of 2003, Intuitive changed its classification of customer training costs from operating expense to cost of goods sold. As a result of this change, fourth quarter 2003 cost of sales included $1.0 million of customer training costs that would have been charged to operating expenses under previous treatment, impacting gross margin by 3.8%. All prior accounting periods are now being presented on a basis consistent with this treatment.
Intuitive ended 2003 with $114 million in cash and short-term investments, reflecting $78 million of net proceeds received from the follow-on stock offering closed during the fourth quarter 2003. Excluding the impact of this funding event, the fourth quarter was approximately cash neutral.
Commenting on the announcement, Lonnie Smith, Chairman and CEO of Intuitive Surgical said, “We are pleased with our record fourth quarter sales and our substantial recurring revenue growth. During the quarter, we substantially completed the Computer Motion integration, settled the Brookhill Wilk lawsuit, and added significant cash resources with a successful follow-on stock offering. At this stage, we are better positioned than ever to follow through on the promise of robotic surgery.”
The company will also announce these results at a conference call today at 1:30 PM PST. The dial-in numbers for the call are 877-909-3508 for participants located in the U.S. and 484-630-4228 for participants located outside the U.S. The passcode is ISRG and the meeting leader is Mr. Lonnie Smith. To access financial information that will be discussed on the call, please visit Intuitive Surgical’s website at www.intuitivesurgical.com.
About Intuitive’s Products:
Theda Vinci® Surgical System consists of a surgeon’s viewing and control console having an integrated, high-performance InSite® 3-D vision system, a patient-side cart consisting of three or four robotic arms that position and precisely maneuver endoscopic instruments and an endoscope, and a variety of articulating EndoWrist® Instruments. By integrating computer-enhanced technology with surgeons’ technical skills, Intuitive believes that its system enables surgeons to perform better surgery in a manner never before experienced. The da Vinci® Surgical System seamlessly and directly translates the surgeon’s natural hand, wrist and finger movements on instrument controls at the surgeon’s console outside the patient’s body into corresponding micro-movements of the instrument tips positioned inside the patient through small puncture incisions, or ports.
TheAesop® Endoscope Positioner is a voice-activated robotic arm that automates the critical task of endoscope positioning, providing the surgeon with direct control over a smooth, precise and stable view of the internal surgical field.
Page 3 of 7
TheHermes® Control Center is a centralized system designed to voice control a series of networked “smart” medical devices.
# # #
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including the following: timing and success of product development and market acceptance of developed products; regulatory approvals, clearances and restrictions; guidelines and recommendations in the health care and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which Intuitive Surgical operates; and unanticipated manufacturing disruptions, delays in regulatory approvals of new manufacturing facilities or the inability to meet demand for products. Words such as “estimate,” “project,” “plan,” “intend,” “expect,” “anticipate,” “believe” and similar expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Intuitive®,da Vinci®,InSite®,EndoWrist®, Zeus®, Hermes®, and Aesop® are registered trademarks of Intuitive Surgical, Inc.
Page 4 of 7
INTUITIVE SURGICAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
3 Months Ended | ||||||||
12/31/03 | 12/31/02 | |||||||
Sales: | ||||||||
Products | $ | 23,627 | $ | 19,448 | ||||
Services | 3,966 | 1,697 | ||||||
Total sales | 27,593 | 21,145 | ||||||
Cost of sales: | ||||||||
Products | 15,901 | 8,517 | ||||||
Services | 2,156 | 1,906 | ||||||
Total cost of sales | 18,057 | 10,423 | ||||||
Gross profit | 9,536 | 10,722 | ||||||
Gross profit % | 34.6 | % | 50.7 | % | ||||
Operating costs and expenses: | ||||||||
Selling, general, and administrative | 10,417 | 9,691 | ||||||
Research and development | 4,732 | 4,026 | ||||||
Total operating costs and expenses | 15,149 | 13,717 | ||||||
Loss from operations | (5,613 | ) | (2,995 | ) | ||||
Other income, net | 758 | 395 | ||||||
Net loss | $ | (4,855 | ) | $ | (2,600 | ) | ||
Net loss per share - basic and diluted | $ | (0.16 | ) | $ | (0.14 | ) | ||
Weighted average shares outstanding used to compute net loss per share - basic and diluted | 30,616 | 18,321 | ||||||
Page 5 of 7
INTUITIVE SURGICAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Fiscal Year Ended | ||||||||
12/31/03 | 12/31/02 | |||||||
Sales: | ||||||||
Products | $ | 80,586 | $ | 66,407 | ||||
Services | 11,089 | 5,615 | ||||||
Total sales | 91,675 | 72,022 | ||||||
Cost of sales: | ||||||||
Products | 39,977 | 31,183 | ||||||
Services | 7,669 | 6,938 | ||||||
Total cost of sales | 47,646 | 38,121 | ||||||
Gross profit | 44,029 | 33,901 | ||||||
Gross profit % | 48.0 | % | 47.1 | % | ||||
Operating costs and expenses: | ||||||||
Selling, general, and administrative | 39,719 | 37,327 | ||||||
Research and development | 16,190 | 16,793 | ||||||
Total operating costs and expenses | 55,909 | 54,120 | ||||||
Loss from operations | (11,880 | ) | (20,219 | ) | ||||
Other income, net | 2,257 | 1,798 | ||||||
Net loss | $ | (9,623 | ) | $ | (18,421 | ) | ||
Net loss per share - basic and diluted | $ | (0.41 | ) | $ | (1.01 | ) | ||
Weighted average shares outstanding used to compute net loss per share - basic and diluted | 23,626 | 18,229 | ||||||
Page 6 of 7
INTUITIVE SURGICAL, INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
12/31/03 | 12/31/02 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 12,165 | $ | 9,007 | ||||
Short-term investments | 101,614 | 41,832 | ||||||
Accounts receivable, net | 26,820 | 16,887 | ||||||
Inventories, net | 8,788 | 8,738 | ||||||
Prepaid expenses | 3,203 | 1,912 | ||||||
Total current assets | 152,590 | 78,376 | ||||||
Property and equipment, net | 10,288 | 10,388 | ||||||
Intangible assets, net | 8,089 | 2,568 | ||||||
Goodwill | 143,106 | — | ||||||
Other assets | 921 | 249 | ||||||
Total assets | $ | 314,994 | $ | 91,581 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 12,455 | �� | $ | 9,282 | |||
Accrued compensation and employee benefits | 4,667 | 4,666 | ||||||
Warranty accrual | 702 | 2,269 | ||||||
Restructuring accrual | 971 | — | ||||||
Other accrued liabilities | 3,024 | 3,497 | ||||||
Deferred revenue | 11,345 | 4,638 | ||||||
Current portion of notes payable | 1,030 | 1,511 | ||||||
Total current liabilities | 34,194 | 25,863 | ||||||
Long-term notes payable | 695 | 1,838 | ||||||
Long-term deferred revenue | 1,148 | 200 | ||||||
Stockholders’ equity | ||||||||
Common stock | 33 | 18 | ||||||
Preferred stock | — | — | ||||||
Additional paid-in capital | 416,559 | 191,038 | ||||||
Deferred compensation | (99 | ) | (223 | ) | ||||
Accumulated deficit | (138,414 | ) | (128,791 | ) | ||||
Accumulated other comprehensive income | 878 | 1,638 | ||||||
Total stockholders’ equity | 278,957 | 63,680 | ||||||
Total liabilities and stockholders’ equity | $ | 314,994 | $ | 91,581 | ||||
Page 7 of 7